Larimar Therapeutics
LRMR
96 hedge funds and large institutions have $655M invested in Larimar Therapeutics in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 22 reducing their positions, and 9 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 22
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
12% more call options, than puts
Call options by funds: $4.43M | Put options by funds: $3.95M
8% more funds holding
Funds holding: 89 → 96 (+7)
12% less capital invested
Capital invested by funds: $740M → $655M (-$85.2M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$27M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.9M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
+$17.2M |
| 4 |
Axa
Paris,
France
|
+$9.83M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$7.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$112M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$23.1M |
| 3 |
DM
Deerfield Management
New York
|
-$17.1M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$5.55M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$5.54M |
LRMR Hedge Fund Activity: Q3 2015 in Review
96 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2015, worth a combined $655M — down 12% from $740M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LRMR positions and 9 closed out — a net gain of 7 holders — while 47 added to existing stakes and 22 trimmed.
The largest buyer was Franklin Resources, adding an estimated $27M. The largest seller was Third Rock Ventures, cutting an estimated $112M.
- 96 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2015, up from 89 in Q2 2015.
- Funds reported $655M of Larimar Therapeutics stock for Q3 2015, down 12% quarter-over-quarter.
- 16 funds opened new Larimar Therapeutics positions in Q3 2015 and 9 closed out, a net change of +7 holders.
- The largest Larimar Therapeutics buyer in Q3 2015 was Franklin Resources, an estimated $27M added.
- The largest Larimar Therapeutics seller in Q3 2015 was Third Rock Ventures, an estimated $112M sold.
Based on aggregated 13F filings for Q3 2015.